| Name | Title | Contact Details |
|---|
Tristar Dental Laboratory, Inc. is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Waterloo Healthcare is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Volpara Health Technologies Limited is a leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Every day, Volpara software helps clinicians better understand their patients and administrators better understand their practices. Volpara Health Technologies Limited (formerly Matakina Technology Limited) is a research, development, and manufacturing company based in Wellington, New Zealand. With a diverse research team led by internationally recognized experts in medical physics, as well as proprietary medical imaging technology covered by multiple patents and trademarks, we apply science to the solving of clinical problems around the world. Volpara Health Technologies Limited holds certification to ISO13485 and is a US FDA–registered establishment whose products are listed accordingly. In addition, our products hold CE Marking under European Medical Device Directive 93/42/EEC. Volpara Solutions Limited is our wholly owned sales and marketing subsidiary.
Perseon Corporation invests its resources in fighting humanity`s worst disease: cancer. Perseon`s people are dedicated to finding innovative technologies and means to deliver energy solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.